A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
Public ClinicalTrials.gov record NCT02391480. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or combination therapy in disease specific expansion cohorts.
Study identification
- NCT ID
- NCT02391480
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2015 (Actual)
- Primary completion
- Jul 5, 2019 (Actual)
- Completion
- Jul 5, 2019 (Actual)
- Last update posted
- Nov 29, 2019
2015 – 2019
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare /ID# 132963 | Scottsdale | Arizona | 85258-4566 | — |
| City of Hope /ID# 154053 | Duarte | California | 91010 | — |
| UC Davis Comp Cancer Ctr /ID# 154644 | Sacramento | California | 95817 | — |
| Yale University /ID# 136982 | New Haven | Connecticut | 06510 | — |
| University of Chicago /ID# 155453 | Chicago | Illinois | 60637-1443 | — |
| Indiana Univ School Medicine /ID# 132946 | Indianapolis | Indiana | 46202 | — |
| Duke Univ Med Ctr /ID# 154647 | Durham | North Carolina | 27705 | — |
| Mary Crowley Cancer Research /ID# 154059 | Dallas | Texas | 75230 | — |
| Univ TX, MD Anderson /ID# 132276 | Houston | Texas | 77030 | — |
| UT MD Anderson Cancer Center /ID# 164122 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02391480, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2019 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02391480 live on ClinicalTrials.gov.